Aim Immunotech Stock News

OCALA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape

AIM ImmunoTech Inc (NYSE:AIM) said data from a study evaluating the direct effects of its flagship drug candidate Ampligen (rintatolimod) on human pancreatic ductal adenocarcinoma (PDAC) cells has b

OCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape

Company to participate in live panel, “Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology,” on Monday, March 28th at 12:00 PM ET Company to participate in

迄今为止的数据表明Ampligen®(rintatolimod)可能成为晚期胰腺癌患者系统化疗后的一种潜在的有效维持疗法

これまでに確認されたデータは、アンプリジェン（アンプリゲン）（Ampligen®）（リンタトリモッド（rintatolimod））が進行性膵臓がん患者の全身化学�

The FDA has lifted the clinical hold on AIM ImmunoTech Inc's (NYSE: AIM) investigational new drug (IND) application for a Phase 2 study of Ampligen for locally advanced pancreatic cancer (AMP-270)

Data seen to date indicates that Ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer

AIM ImmunoTech Inc (NYSE:AIM) revealed that it has received a notification from the US Food and Drug Administration (FDA) stating that the clinical hold on the company's investigational new drug (IND)

Ampligen® （rintatolimod）正在荷兰伊拉斯谟医疗中心（Erasmus Medical Center）医疗检查机构批准的早期获取计划（EAP）中作为治疗胰腺癌患者的单药疗法接受�

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape

AIM ImmunoTech Inc (NYSE: AIM ) announced the publication of positive data from a single-center named patient program treating advanced and metastatic pancreatic cancer patients. The study found that the median overall survival in the Ampligen group was 19 months, compared to a historical control group and subgroup (7.5 and 12.5, respectively). At six weeks, the Systemic Immune-Inflammation Index (SIII) and Neutrophils … Full story available on Benzinga.com

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AMERICAN ) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, announced today that oncology experts from Roswell Park Comprehensive Cancer Center will present findings from two ongoing clinical studies involving an AIM ImmunoTech Inc. drug candidate, Ampligen® (also known as rintatolimod) at the American Association for Cancer Research (AACR) Annual Meeting 2022 , being held April 8-13, 2022, in New Orleans, Louisiana. Research led by Roswell Park medical oncologists Shipra Gandhi, MD , and Sarbajit Mukherjee, MD, MS , in collaboration with senior investigator Pawel Kalinski, MD, PhD , Chair of Immunology at Roswell Park, has been accepted for presentation as late-breaking poster abstracts at … Full story available on Benzinga.

AIM ImmunoTech (AIM) said Ampligen following FOLFIRINOX, a chemotherapy combination, showed improved survival rates in patients with pancreatic cancer compared to matched controls…